
|Videos|May 12, 2016
The Long-Term Impact of Biosimilars on Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.
Advertisement
Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADA 2026: Key Pharmacotherapy Advances in Type 1 and Type 2 Diabetes
2
CagriSema Outperforms Semaglutide in Lowering HbA1C, Reducing Weight Across REIMAGINE Trials
3
ADA 2026: Lipid Management and Cardiovascular Prevention Updates for People With Diabetes
4
McKesson ideaShare 2026: Why Automation and AI Are Reshaping the Dispensing Experience
5




















































































































